Conclusion
1.No nanomedicine that combines two or more drugs in a single platform has been approved for clinical use yet. Some of the designs of the nanoplatforms used for these combinations are fairly complex thereby limiting excitement in the context of successful clinical development. Most of the designs and synthesis procedure outlined provide little to no ratiometric control of the two or more drugs that are trapped inside these nanoparticles. Clearly, more optimization is needed for such nano-combinations to find maximal therapeutic responses.
2.Next generation of nano-combinations need to be easy to manufacture and provide excellent control on drug ratios with exceptional batch-to-batch reproducibility. Another factor rarely considered is, if some of these nanoplatforms are successful in getting clinical.
…
